Unsustainable – or manageable? We don’t yet know how data centres will impact Australia’s environment 
Who should own the knowledge that underpins AI technology? 
Goldman Sachs Forecasts Fed Rate Hike as Inflation Risks Rise 
Physicists zoom into the birth of cosmic rainstorms with new CERN study 
‘Buy now, pay later’ doesn’t feel like debt. For young people, that can be a big problem 
Banking scandal rocks Brazil’s politics and the country’s presidential election in October 
Synthetic data could ease people’s concerns about privacy breaches. But who gets to create it? 
1 in 3 uni students experience serious financial hardship. Could concession cards for all help? 
Big AI wants to slow down AI research. Is it a safety pause or a strategic retreat? 
What is Zionism? The different meanings of a contested term 
Add as a preferred source on Google
For the past six months US small caps are performing better than large counterparts as measured by Russell 2000 and S&P 500 indices. Since late october 2014, Russell 2000 rose 13.7% compared to 4.4% rise in S&P 500. Chart courtesy Sober look
- Investors remain bullish on US stocks, however exercising cautions over stronger US dollar.
- Large corporate houses that have presence across globe are expected to suffer from stronger US dollar as export revenues and royalty payments will get affected.
- According to EPFR, intelligence provider on Global fund statistics after nearly $31.5 billion withdrawal for the sector in 2014, this year they have started attracting flows. Investors expect small companies to benefit most out of US recovery amid stronger dollar.
- Average sales per share is up 6.6% this year for S&P600 companies so far this year, compared to 0.1% for large caps.
- UBS expects earnings for small companies would be in double digit this year whereas average for large caps would remain in single.
- Investors remain most bullish healthcare and pharmaceuticals whereas energy sector is expected to do worst.
- Bluebird bio returned more than 300% since February 2014, followed by Agios Pharma and Achillion Pharma both of which have returned more than 200%.
